Genetic Predictors Address The Wide Variation In Response To Weight Loss Therapy
This article was originally published in Start Up
Executive Summary
A study of gastric bypass patients has identified a gene locus that was significantly associated with less weight loss after the procedure, and two nearby genes that may be regulated in response to the bypass. The findings support the belief that the development of genetic signatures, when added to clinical predictors, can help better determine when to use specific obesity therapies in specific patients.
You may also be interested in...
Obesity Intervention: A New Era Of Discovery And Innovation
Driven by a vast and underserved market in dire need of safer, less-invasive, more effective solutions, manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease. Indeed the obesity intervention paradigm is rapidly changing as ongoing research provides new insights into the underlying mechanisms behind obesity and bariatric surgery, heralding a new era where the primary treatment target for bariatric surgery is becoming disease specific, rather than targeted at obesity alone.
The Fight Against Fat: Start-Ups Look To Serve A Vast Market With Minimally Invasive Bariatric Devices
Start-ups with an array of compelling devices are seeking to provide alternatives to invasive gastric bypass surgery and laparoscopic gastric banding for the millions of morbidly and moderately obese patients – but which ones will make it through the evolving FDA clinical process? In this issue we profile three young companies that hope to succeed: Aspire Bariatrics, EndoSphere, and Vibrynt.
Bariatric Surgery Bests Medical Therapy In Treating Diabetes
The findings come from two studies, including the randomized STAMPEDE trial, funded by Johnson & Johnson and the National Institutes of Health, comparing medical therapy with two forms of surgical treatment – gastric bypass or sleeve gastrectomy.